| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera |
| 09 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2026, AN2 Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting in person or via proxy were the holders of 22,741,535 shares of c... |
| 04 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Oral epetraborole program in polycythemia vera advancing toward Phase 2 |
| 09 Apr 2026 |
8-K: Other Events
AN2 Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares... |
| 20 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 17 Mar 2026 |
8-K: Results of Operations and Financial Condition
AN2 Therapeutics Reports Fourth Quarter and Full Year End 2025 Financial Results and Recent Business and Scientific Highlights |
| 10 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 8, 2026, by and among AN2 Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Exhibit A attached to this Agreement (ea... |
| 29 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway |
| 12 Aug 2025 |
8-K: Financial Statements and Exhibits
Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028 |
| 20 Jun 2025 |
8-K: Unregistered Sales of Equity Securities
AN2 Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Coastlands Capital Partners LP or its registered as... |
| 11 Jun 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Investor Overview June 2025 A N 2 T H E R A P E U T I C S . C O M |
| 27 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 22, 2025, AN2 Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting in person or via proxy were the holders of 23,928,440 shares of c... |
| 13 May 2025 |
8-K: Financial Statements and Exhibits
Cash, cash equivalents, and investments of $78.5 million at March 31,2025 and cash runway anticipated to fund operations into 2028 |
| 01 May 2025 |
8-K: Regulation FD Disclosure
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline |
| 25 Mar 2025 |
8-K: Results of Operations and Financial Condition
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline |
| 05 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...